Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery
and platinum doublet chemotherapy, is associated with high risk of relapse and poor …

Breast cancer is a heterogeneous disease, manifesting in a broad differentiation in
phenotypes and morphologic profiles, resulting in variable clinical behavior. Between 10 …

BACKGROUND A phase 1 trial was used to evaluate a combination of cisplatin,
gemcitabine, and escalating doses of veliparib in patients with untreated advanced …

Objective Determine the maximum tolerated dose (MTD) and recommended phase II dose
(RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced …

BACKGROUND Poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors such as
veliparib are potent sensitizing agents and have been safely combined with DNA‐damaging …

Background Temozolomide (TMZ) is active against glioblastomas (GBM) in which the O6-
methylguanine-DNA methyltransferase (MGMT) gene is silenced. However, even in …

Phase 0 approaches, including microdosing, involve the use of sub-therapeutic exposures
to the tested drugs, thus enabling safer, more-relevant, quicker and cheaper first-in-human …

Background PARP inhibitors are currently evaluated in combination with radiotherapy
and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations …

The poly (ADP‐ribose) polymerase‐1/2 inhibitor veliparib is active against tumors deficient
in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended …

Introduction: PARP1 and BRCA genes are essential genome caretakers and their interaction
has been the first example of synthetic lethality, a genetic concept proposed in the early 20th …